Psoriasis: From the Bench to the Bedside

Dear Colleagues,

Psoriasis is a chronic relapsing inflammatory autoimmune disease involving several genetic, immunological, and environmental factors that primarily affect skin and joints. Psoriasis patients also develop co-morbidities including depression, obesity, diabetes, and cardiovascular and inflammatory bowel disease. For simplicity, it may be attributed to a systemic T-cell mediated autoimmune disease with the innate immune system playing a pivotal role. However, our current understanding of psoriasis is, that it is not driven by one cell type or another, instead well-coordinated crosstalk among many skin-resident cell types such as macrophages, antigen-presenting cells, keratinocytes, dendritic cells, and those that traffic into (monocytes, T cells, neutrophils, etc.) the skin.

There is no cure for psoriasis, but it can be effectively managed by treating patients early in the disease process. Recent immunological and genetic studies have identified IL-17 and IL-23 as key drivers of psoriasis pathogenesis. Current treatment options include topicals, phototherapy, systemic immunosuppressive agents, anti-metabolites, and retinoids. Biological therapies involving targeting key psoriatic cytokines IL-17, IL-23 and TNFα are highly effective against moderate-to-severe psoriasis patients but their efficacy varies among patients and over time, psoriasis can become resistant to individual therapies.

Recent advances in immunological, genetic, microbiome and detection techniques (e.g., NSG, multicolor flow cytometry, CyTof, scRNASeq, etc.) have enabled researchers to dig deeper into the underlying molecular mechanisms of psoriasis. This Special Issue particularly focuses on original research and reviews on the relationship between the immunological and pathological aspects of psoriasis, as well as cutting-edge translation research in the therapeutics arena to cover the following themes:

• Genetic, genomic, epigenomic, proteomic, and cellular mechanism of psoriasis;
• Skin and gut microbiome in modulating homeostasis and immune response in skin;
• Cell therapy, cellular crosstalk among the skin immune and non-immune cells;
• Others, e.g., case reports, commentaries are welcome as well.

Dr. Roopesh Singh Gangwar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Dermato is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• psoriasis
• inflammation
• biologics
• immunotherapy
• autoimmunity
• keratinocyte
• T cells
• psoriatic arthritis
• co-morbidities